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ORIGINAL RESEARCH

Evaluation of Geographic Disparities in Cervical Cancer
Survival Across Maine
Kaylee Underkofler, MD, MPH,1 Jason Lachance, MD2
Department of Obstetrics & Gynecology, University of Rochester Medical Center, Rochester, NY, 2 Department of Obstetrics
& Gynecology, Maine Medical Center, Portland, ME
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Introduction:

National data suggests that there are geographic disparities in oncology care within the United States.
It is unknown whether these disparities present a problem for women with gynecologic malignancies
located in Maine.

Methods:

Data from each cervical cancer case diagnosed or treated under the MaineHealth system between 2007
and 2011 were acquired from the MaineHealth Network Registry. Average annual incidence and 5-year
survival were calculated for each county in Maine and mapped using geographic information systems
software. Next, cases were divided into 2 groups: patients residing less than or equal to 60 miles from
the sole gynecologic oncology practice in Maine and those residing over 60 miles from the practice. The
5-year survival rates of each group were compared using chi-square testing. Demographics and risk
factors of the 2 groups were compared with the 2-sample t-test or Fisher’s exact test.

Results:

The average annual incidence of cervical cancer in each county of Maine between 2007 and 2011
ranged from 0 to 0.91 new cases per 10 000 female persons. The 5-year survival rate within each
county ranged from 0% to 100%. The 5-year survival rate of women with cervical cancer residing less
than or equal to 60 miles from the gynecologic oncology practice based in Maine was 63.0%, while the
rate of those residing farther than 60 miles was 71.9% (P = .12).

Conclusions:

No significant geographic disparities in survival outcomes were found for women diagnosed with cervical
cancer in Maine between 2007 and 2011.
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T

here is a growing emphasis on identifying and
correcting disparities in health care.1 Multiple
types of disparity exist, including gender, racial,
socioeconomic status, and geographic location.
Geographic disparities involve differences in health
status or care access between 2 geographically
defined populations.2 A recent study by Henley
et al. illustrated the extent to which geographic
disparities affect health care in the United States.3
This study examined the difference in mortality
from invasive cancers between metropolitan and
nonmetropolitan rural counties across the nation.
It concluded that rural counties, despite having
lower incidence rates, had higher mortality rates
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than metropolitan counties. These findings suggest
that geographic disparities in oncology care are a
nationwide problem.
The state of Maine is primarily rural, with 61.3% of
the population residing in areas comprising less
than 2500 individuals.4 Geographic disparities are
of particular concern in states like Maine due to
the shortage of health care providers in rural areas
and the location of specialty providers in urban
areas.5 Gynecologic oncologists are among those
specialty providers located to urban areas due to
the need for volume, infrastructure for complex
surgery, care coordination with other medical
specialties, and ancillary facilities that can conduct
chemotherapy infusion and radiation therapy.
A recent study found that 36% of counties in the
United States are located greater than 50 miles
1
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from a gynecologic oncologist, putting 14.8 million
women at risk of geographic disparities in care if
they were to develop a gynecologic malignancy.6
Given this location of gynecologic oncologists, and
the reported national correlation between rurality
and poor cancer outcomes, there is reasonable
concern that geographic disparities might exist for
women with gynecologic malignancies in Maine.3
It is unknown whether patients with gynecologic
malignancies living in the rural areas of Maine (or
other states) face worse outcomes than those who
reside closer to gynecologic oncology practices.
Geographic disparities might occur for women with
many different types of cancer. However, there is
greater concern for women with cervical cancer due
to the nature of treatment. Cervical cancer is the third
leading gynecologic malignancy in the developed
world, and its treatment is complex.7 Treatment is
multimodal, frequently requiring some combination
of surgery, chemotherapy, and/or radiation therapy.
Definitive chemoradiation for cervical cancer is
complex. It typically involves daily pelvic radiation
therapy for approximately 25 fractions and weekly
cisplatin-sensitizing chemotherapy, followed by
intracavitary brachytherapy.8 Surgery and radiation
therapy can be done in only a limited number of
facilities, with the lone gynecologic oncology
practice in the state or an affiliated radiation
oncologist typically located in an urban area. Due to
the complexity of this care-delivery model, traveling
to access services is particularly difficult for patients
living in rural areas far from gynecologic oncology
care and the necessary adjunctive services. A
single-site study published in 2015 revealed that
treatment completion for women with gynecologic
cancers, while high overall, depended on the
distance to treatment.9
We hypothesized that among women with cervical
cancer living in Maine, survival rates may be worse
for women residing far from their gynecologic
oncologist when compared to those residing
nearby.3 We conducted an observational pilot study
to determine whether outcomes differ for a cohort of
patients in Maine who were diagnosed with cervical
cancer based on the distance of their residence
from their primary gynecologic oncology practice.
This sole practice was located in the southern and
most populated part of the state.
https://knowledgeconnection.mainehealth.org/jmmc/vol2/iss2/3
DOI: 10.46804/2641-2225.1060

METHODS
This study was approved by the Maine Medical
Center Institutional Review Board in March 2018.
Data collection and management
Data by MaineHealth Oncology Information
Services. All patients diagnosed or treated by
a MaineHealth provider for a malignancy are
automatically entered into this registry. The
Maine Health Network Registry includes 89% of
all gynecologic oncology patients in the state of
Maine. All these patients were treated by the sole
gynecologic oncology practice in Maine under the
MaineHealth system and included in the study. The
11% of patients not included in the registry sought
treatment outside of the MaineHealth system and
were excluded from the study.
All women residing in Maine who were diagnosed
with cervical cancer and seen by a MaineHealth
gynecologic oncologist between 2007 and 2011
were eligible for inclusion in the study (n = 182).
This date range was chosen to allow for calculation
of 5-year survival for all patients over a 5-year time
span. This span was chosen to increase the number
of patients in the study and prevent changes in
treatment recommendations over time from being
a significant confounder. Patients were excluded
from the study if their survival was unable to be
calculated due to loss to follow-up (n = 26). Thus,
156 patients were enrolled in the study. Variables
extracted from each case included patient age,
date of diagnosis, disease stage, zip code, county,
vital status, time from diagnosis to most recent
contact, insurance status, tobacco history, and
race. Computed variables for each case included
5-year survival status and distance in miles from
zip code to the sole gynecologic oncology practice
in Maine. Additional variables needed for incidence
calculations included female population of each zip
code and county, which were acquired from the
United States Census Bureau.10 Data was stored
and accessed using Microsoft Excel.
Data analysis
The average annual incidence of cervical cancer
between 2007 and 2011 was calculated for each zip
code and county in Maine. This calculation used the
date of diagnosis for each case and 2010 Census
tract data for the general female population of each

2
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geographic unit. The average annual incidence of
each zip code and county were also mapped to
visually represent this data. Incidence rates were
averaged over the 5-year study to protect patient
confidentiality.
To explore the relationship between the distance
to treatment and survival, the distance from the zip
code to the primary gynecologic oncology practice
for each patient was used to separate cases into
2 study groups: patients residing greater than 60
miles from the practice and patients residing less
than or equal to 60 miles away. A distance cutoff
of 60 miles was chosen as an estimate of the
minimum distance that would burden patients
needing to frequently obtain health care, and to
ensure each group had a reasonable number of
cases to maximize statistical power. The 5-year
survival rate for each of the 2 groups was calculated
using the 5-year survival status of each case within
the groups. The survival rates were also calculated
based on each zip code and county within Maine,
and the rates were mapped using geographic
information systems (GIS). Survival rates were
averaged over the 5-year study to protect patient
confidentiality.
Demographic and outcome data were summarized
using descriptive statistics. Continuous data was
shown as mean, and categorical data was shown
as frequency (n, %). Differences between the 2
distance groups were compared by chi-square (χ2)
test or Fisher’s exact test as appropriate (categorical
data), or by t-test (continuous data). A significance
level of .05 was chosen for all tests. All statistical
tests were done using the data analysis tools within
Microsoft Excel.
Data mapping
Maps were produced with the GIS software Global
Mapper by Blue Marble Geographics (Hallowell,
ME) using the calculated average annual incidence
rate and 5-year survival rate for each zip code and
county in Maine. Because the small population
sizes of several counties in Maine could jeopardize
patient confidentiality and identification, maps of zip
code data were not included in this report.

RESULTS
A select number of demographic variables and
risk factors were compared between the 2 study
groups: patients located less than or equal to 60
Published by MaineHealth Knowledge Connection, 2020

miles from the sole gynecologic oncology practice
and patients located greater than 60 miles away
(Table 1). These variables included age, race,
insurance status, cancer stage, and tobacco use
history. The mean difference in age between the 2
groups, calculated by 2-sample t-testing, was 0.69
(P = .79, 95% CI [-4.31, 5.68]). Differences in race,
insurance status, disease stage, and tobacco use
history were compared using Fisher’s exact test (P
= .59, .77, .70, and .86, respectively). There were
no significant differences between the 2 groups.
The average annual incidence of cervical cancer
in each county of Maine between 2007 and 2011
ranged from 0 new cases per 10 000 female
persons in Washington and Piscataquis Counties
to 0.91 new cases per 10 000 female persons in
Somerset County (Table 2, Figure 1). The 5-year allstage survival rate for women with cervical cancer
in the state of Maine between 2007 and 2011 was
67%. When examining each county of Maine, the
5-year survival ranged from 0% in Oxford County to
100% in Hancock and Aroostook Counties (Table
2, Figure 2).
The 5-year survival rates of the 2 distance-based
groups of cervical cancer patients were calculated.
The 5-year survival rate of women residing less than
or equal to 60 miles from the practice was 63.0%,
while the rate of women residing farther than 60
miles from the practice was 71.9% (χ = 1.30, P =
.12).

DISCUSSION
Calculations and mapping of average annual
incidence revealed that new cases of cervical
cancer are fairly widespread across the state (Table
1, Figure 1). The 2 counties with an incidence of
0 new cases per 10 000 female persons are rural,
and thus the low incidence may reflect smaller
sample sizes rather than, for example, superior
preventive care. Somerset County is rural and has
a disproportionately high number of new cervical
cancer cases. While local needs assessments in
this area may help to determine the cause of this
high incidence rate, the incidence in rural counties
should be interpreted with caution. Given the
small overall population, these rates are generally
unstable over time.11
Survival maps produced with GIS did not suggest
a correlation between distance to the primary
gynecologic oncology practice and 5-year survival.
3
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Table 1. Comparison of selected demographics and risk factors between study groups.
Variable
Age, mean
Race, no (%)
White
Black
Other
Insurance status, no (%)
Insured
Not insured
Unknown
Disease stage, no (%)
I
II
III
IV
Unknown
Tobacco use history, no (%)
History of use
No history of use
Unknown

Patients ≤ 60 miles from
Maine GO
(n = 92)
51.83

Patients > 60 miles
from Maine GO
(n = 64)
51.14

88 (96%)
2 (2%)
2 (2%)

64 (100%)
0 (0%)
0 (0%)

P value
.79
.59

.77
79 (86%)
12 (13%)
1 (1%)

58 (91%)
6 (9%)
0 (0%)
.70

40 (43%)
14 (15%)
24 (26%)
13 (14%)
1 (1%)

25 (39%)
10 (16%)
15 (23%)
11 (17%)
3 (5%)
.86

51 (55%)
35 (38%)
6 (7%)

35 (55%)
26 (41%)
3 (5%)

*Percentages within subgroups that do not add up to exactly 100% are due to rounding.
GO, gynecologic oncologist.

In fact, the highest 5-year survival rate was in
the farthest county (Aroostook), while the lowest
rate was in the county much closer to treatment
centers (Oxford). This observation contradicts the
hypothesis that survival rates would be lower for
those who reside farther from care.
Statistical comparison of 5-year survival rates
between the 2 study groups further supported
that survival rates are not lower for patients with
cervical cancer who reside farther from care in
Maine. We were surprised that the 5-year survival
rate appeared higher for patients residing further
from care. However, further analysis using chisquare testing yielded a P value of .12, indicating
that there was no significant difference in survival
between the 2 study groups. Of note, both survival
rates are fairly consistent with the national 5-year
survival rate for all-stage cervical cancer of 68%.12
https://knowledgeconnection.mainehealth.org/jmmc/vol2/iss2/3
DOI: 10.46804/2641-2225.1060

This study did not reveal geographic disparities in
the survival of cervical cancer patients in Maine.
However, disparities occur elsewhere and may
still exist throughout the state for patients with
other gynecologic malignancies or serious chronic
illnesses. Geographic disparities and research
regarding them remain significant for this reason
and several others. First, research addressing
this phenomenon allows providers to identify
whether the specific populations they serve may be
vulnerable to disparities in care. A problem cannot
be corrected if we do not know it exists. Second,
studies that illustrate geographic variations in
incidence and survival could indicate where more
services are needed. If differences in survival are
detected, they could help to establish oncology
outreach clinics, introduce infusion capabilities or
radiation modalities to existing health care centers,
or invest in treatment housing (similar to the Ronald
McDonald House model) for far-traveling patients.13
4
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Table 2. Average annual incidence of cervical cancer and 5-year survival rates of patients with cervical
cancer in Maine by county, 2007-2011.
County

No. of new
cases

Female
population

Average annual
incidence per
10 000
female persons

Androscoggin

15

55 036

0.55

12

80%

Aroostook

6

36 510

0.33

6

100%

Cumberland

40

145 062

0.55

24

60%

Franklin

6

15 722

0.76

5

83%

Hancock

3

27 753

0.29

3

100%

Kennebec

25

62 663

0.77

16

64%

Knox

3

20 067

0.30

1

30%

Lincoln

7

17 573

0.80

5

71%

Oxford

3

29 148

0.27

0

0%

Penobscot

3

78 039

0.08

2

67%

Piscataquis

0

8838

0.00

--

--

Sagadahoc

6

18 211

0.66

2

33%

Somerset

12

26 323

0.91

7

58%

Waldo

5

19 781

0.51

4

80%

Washington

0

16 658

0.00

--

--

York

22

101 128

0.44

17

77%

Geographic disparity studies are particularly
valuable if different specialties find they need similar
resources in remote locations. For example, if
future geographic studies of gynecologic and other
cancers suggest a need for a new chemotherapy
infusion site in the northern regions of Maine,
they could drive efforts to establish a new site for
treatment.
There are limitations within this study. The first is
the small sample size of cervical cancer patients
and resulting limited statistical power. While we
did observe every case of cervical cancer in the
MaineHealth Network Registry between 2007 and
2011, cervical cancer has a relatively low incidence
in the United States thanks to the advent of the
Pap smear.14 This low incidence, and thus small
sample size, limited our comparison to 2 groups
and also influenced the distance cutoff to maximize
statistical power. The second limitation of this study
involved the constraints of using registry data.
The MaineHealth Network Registry only includes
cases that are diagnosed or treated under the
umbrella of MaineHealth, which, for gynecologic
malignancies, is only 89% of the patients residing
Published by MaineHealth Knowledge Connection, 2020

No. of
patients
surviving
5 years

5-year
survival rate

in Maine. Therefore, the study did not include every
cervical cancer patient within the state of Maine.
However, it did include every patient cared for by
the sole gynecologic oncology practice based in
Maine. Additionally, when using registry data, one
must sacrifice data variables of interest for the
convenience of access. For example, it would have
been useful to examine other demographic and
risk factor variables for cervical cancer patients,
such as socioeconomic status and Pap smear
history. It would have also been useful to know
the treatment regimen for these patients and
whether it influenced their survival. For example, in
patients with intermediate-risk cervical cancer, we
could consider whether geographic consideration
influenced decisions between treating with radical
hysterectomy or definitive chemoradiation. These
variables were not recorded in the registry and could
not be incorporated into analysis. Future efforts
could involve a chart review, enabling these gaps
to be filled. The third limitation of this study was loss
to follow-up. Between 2007 and 2011, there were
26 patients diagnosed with cervical cancer in Maine
who could not be included in the analysis because
their vital status could not be assured. Many of
5
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Figure 1. Map of average annual
incidence of cervical cancer in Maine by
county, 2007-2011.

Figure 2. Map of 5-year survival rates of
patients diagnosed with cervical cancer
in Maine by county, 2007-2011. Counties
in white did not have any diagnosed
cases.

https://knowledgeconnection.mainehealth.org/jmmc/vol2/iss2/3
DOI: 10.46804/2641-2225.1060
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these patients were seen once for their surgery
and not seen by their gynecologic oncologist again.
Instead, they followed up in local rural settings due
to geographic considerations. Therefore, these
patients’ vital status was not updated in the registry.
It does not appear that differences in distance to
treatment were influential: 14 of the patients lost
to follow-up resided within 60 miles of the Maine
gynecologic oncology practice (13.2% of the nearby
group), and 12 resided over 60 miles (15.8% of the
far group).

as Dr. Wendy Craig for assistance with statistical
methods.
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